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Abstract: PURPOSE To assess whether smoking status affects 1-year visual outcomes in eyes treated with
vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration. METH-
ODS Retrospective analysis of data from a prospectively designed, multicenter, observational database.
Nine hundred and eighty seven treatment-naive eyes of patients with neovascular age-related macular
degeneration were tracked by the Fight Retinal Blindness! outcome registry in Australia, New Zealand,
Singapore, and Switzerland who had documented smoking status at baseline and commenced vascular
endothelial growth factor inhibitor therapy from January 2006 to December 2016. Generalized additive
models were used to display visual acuity results. RESULTS There was a significant difference in mean
improvement in visual acuity at 12 months between nonsmokers, ex-smokers, and current smokers (7.7
vs. 6.1 vs. 3.5 letters of change; P = 0.046) among patients who completed 12 months of treatment when
adjusted for age, baseline visual acuity, and choroidal neovascular membrane lesion type and nested for
practice. There was no significant difference in the median number of injections over 12 months of treat-
ment by smoking status. Current smokers were a mean of 6.2 years younger than nonsmokers when they
started treatment (P < 0.001). CONCLUSION This study found inferior 12-month visual outcomes in
patients who continued to smoke while receiving vascular endothelial growth factor inhibitor therapy for
neovascular age-related macular degeneration.
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Purpose: To assess whether smoking status affects 1-year visual outcomes in eyes
treated with vascular endothelial growth factor inhibitors for neovascular age-related
macular degeneration.
Methods: Retrospective analysis of data from a prospectively designed, multicenter,
observational database. Nine hundred and eighty seven treatment-naive eyes of patients
with neovascular age-related macular degeneration were tracked by the Fight Retinal
Blindness! outcome registry in Australia, New Zealand, Singapore, and Switzerland who
had documented smoking status at baseline and commenced vascular endothelial growth
factor inhibitor therapy from January 2006 to December 2016. Generalized additive models
were used to display visual acuity results.
Results: There was a significant difference in mean improvement in visual acuity at 12
months between nonsmokers, ex-smokers, and current smokers (7.7 vs. 6.1 vs. 3.5 letters
of change; P = 0.046) among patients who completed 12 months of treatment when
adjusted for age, baseline visual acuity, and choroidal neovascular membrane lesion type
and nested for practice. There was no significant difference in the median number of
injections over 12 months of treatment by smoking status. Current smokers were a mean
of 6.2 years younger than nonsmokers when they started treatment (P , 0.001).
Conclusion: This study found inferior 12-month visual outcomes in patients who
continued to smoke while receiving vascular endothelial growth factor inhibitor therapy for
neovascular age-related macular degeneration.
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A
ge, genetic factors, and smoking are the main
known risk factors for the development of age-
related macular degeneration (AMD), with smoking
being the major modifiable risk factor.1–3 Smoking
has consistently been associated with the pathogenesis
of AMD, with proposed mechanisms including de-
creases in macular xanthophyll, decreased choroidal
blood flow, and reduced antioxidants.4 Nicotine may
also directly potentiate subretinal inflammation and
platelet-derived growth factor–mediated upregulation
of endothelial smooth muscle cell proliferation.5,6
Although cigarette smoking is a well-documented
risk factor for neovascular AMD (nAMD),2 its impact
on the efficacy of vascular endothelial growth factor
(VEGF) inhibitor agents has not been firmly estab-
lished. The odds ratio of developing nAMD across
population based cross-sectional studies has been esti-
mated to be 2.5 to 7.0 for smokers compared with
nonsmokers.7–12 The effect of smoking on VEGF
inhibitor treatments was not analyzed in these studies.
Quitting smoking reduces the risk of developing
AMD, while higher-pack year smokers have .5-fold
risk of developing nAMD in their second eye.7,13
None of the pivotal phase three studies of ranibizu-
mab or aflibercept to treat nAMD studied smoking
status as a variable for treatment response.14–20 A
single-center South Korean analysis of 125 eyes re-
ported that current cigarette smoking was associated
1
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with poor visual acuity improvement with VEGF in-
hibitors for exudative AMD, although only 14 smok-
ers were included.21 A subgroup analysis of 1,105
patients from the CATT study found no significant
difference of mean visual acuity change at 12 months,
although this was not adjusted for differences in
groups at baseline.22 The purpose of this study was
to investigate the effect of smoking status on real-
world outcomes of VEGF inhibitor agents for nAMD




This was an observational study of treatment-naive
eyes from the prospectively designed FRB! registry
that had received intravitreal VEGF inhibitor treatment
for nAMD. The FRB! registry is a web-based
multinational database where the treating ophthalmol-
ogist records patient information and treatment out-
comes.23 The number of letters read on a logarithm of
the minimum angle of resolution visual acuity chart
(best of uncorrected, corrected, or pinhole), treatment
performed, activity of the choroidal neovascular
lesion, and any procedures or adverse events were
mandatorily collected at each patient visit.23 This
study was approved by the Human Research Ethics
Committees of the University of Sydney, the Royal
Victorian Eye and Ear Hospital, the Royal Australian
and New Zealand College of Ophthalmologists, the
University Hospital, Zurich, and SingHealth, Singa-
pore. Ethics committees in Australia and New Zealand
approved the use of “opt out” patient consent.
Patient Selection and Variables
We studied patients with treatment-naive nAMD
from Australia, New Zealand, Singapore, and Switzer-
land who had documented smoking status and started
treatment from January 2006 to December 2016 to
allow for at least 1 year of treatment. Smoking status
was determined at the time of their baseline visit and
included current smokers, ex-smokers, and non-
smokers. Those who continued follow-up for at least
365 days were defined as “completers,” while those
with less than 365 days of follow-up were
“noncompleters.”
Study Measurements
Patient age, smoking status, sex, visual acuity,
lesion type, size, and activity were recorded at the
baseline visit, which is when treatment was started.
Treatments used, along with visual acuity and activity
(“active” or “inactive”) of choroidal neovascular mem-
brane (CNVM), were recorded at each follow-up visit.
Lesion activity status was graded by the treating oph-
thalmologist at each visit, with lesions graded as active
if there were “features such as subretinal or intraretinal
fluid or new hemorrhage that suggested that the CNV
lesion was active.” Idiopathic polypoidal choroidal
vasculopathy was diagnosed using indocyanine green
angiography.
Outcomes
The primary outcome was mean change in visual
acuity after 12 months of treatment for patients with
different smoking histories. Secondary outcomes
included the mean change in visual acuity at 24
months, where available, the frequency of injections
required for patients of different smoking histories and
the proportion of visits at which the choroidal neo-
vascularization lesion was graded as active.
Statistical Analysis
Descriptive statistics were described using the
mean, SD, 95% confidence interval (CI), median, first
and third quartiles (Q1, Q3), and percentages where
appropriate. One-way analysis of variance, chi-square,
pairwise t-tests, or Wilcox tests (adjusted for multiple
comparisons) were used as appropriate to compare
demographics between smoking groups. The visual
acuity closest to the 12-month time point, or the last
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observation carried forward for noncompleters, was
used as the visual acuity at 12 months for cross-
sectional analyses and to present raw, unadjusted out-
comes, including mean visual acuity change, the pro-
portion of eyes gaining or losing .10 letters, and the
proportion of eyes with visual acuity .70 or ,35
letters. Generalized additive models were used to dis-
play the visual acuity throughout the follow-up and
included longitudinal data from both completers and
noncompleters.
Cross-sectional analysis of mean visual acuity
improvement at 12 and 24 months between smoking
status groups was analyzed using mixed-models
controlling for the possible confounders of age, lesion
type, and visual acuity at baseline, with nesting of eyes
within patients (for bilateral disease) and patients
within practices. This was followed by post hoc
pairwise comparisons between smoking groups. A
comparison of the visual acuity curves over time using
longitudinal generalized additive models including
data from completers and noncompleters was also
performed. The same confounding variables were
included in the model, with additional random slope
and intercept terms for repeated measurements in each
eye. Time to first inactive CNVM grading was plotted
using Kaplan–Meier survival analysis while the pro-
portion of visits in which the lesion was graded as
active was compared using logistic regression. The
number of injections received was analyzed using
Poisson regression.
The Holm–Bonferroni correction was used for all
pairwise comparisons. All analyses were performed
using R version 3.4.3.24
Results
Patient Characteristics
Data from 987 eyes from 837 patients recorded at 43
participating practices within Australia, New Zealand,
Singapore, and Switzerland initiating treatment with
VEGF inhibitors between January 2006 and December
2016 were included in the analysis. Of these, 756 eyes
(77%) completed at least 12 months of follow-up.
Current smokers were a mean of 6.2 years younger at
presentation than nonsmokers (P , 0.001; Table 1).
The baseline visual acuity and lesion size on fundus
fluorescein angiography or optical coherence tomog-
raphy were significantly different between smoking
groups; smokers had lower visual acuity and larger
lesions at baseline (Table 1). There was no significant
difference in the initial VEGF inhibitor used between
the different groups (Table 1). Treatment frequency
Table 1. Baseline Demographics by Smoking Status
All Patients Nonsmoker Ex-smoker Smoker P
Eyes, no. (%) 987 594 (60.1) 265 (26.8) 128 (13.0)
Patients, no. (%) 837 502 (60.0) 232 (27.7) 103 (12.3)
Female, no. (%) 577 (58.5) 422 (71) 108 (40.8) 47 (36.7) ,0.001*
Age, mean (SD) 77.4 (8.9) 78.3 (9) 78.1 (8.5) 72.1 (7.4) ,0.001†
Baseline VA, mean letters (SD) 56.7 (20.6) 56 (20.9) 59.3 (18.9) 54.5 (22.0) 0.036†
Initial VEGF inhibitor
Ranibizumab, no. (%) 434 (44.0) 262 (60.4) 122 (28.1) 50 (11.5) 0.744*
Bevacizumab, no. (%) 322 (32.6) 196 (60.9) 81 (25.2) 45 (14.0)
Aflibercept, no. (%) 231 (23.4) 136 (58.9) 62 (26.8) 33 (14.3)
CNVM lesion size
CNVM size, median mm 2,300 2,227.5 2,336 2,515.5 0.032†
CNVM size, Q1–Q3 1,498.5–3,705 1,420.5–3,582.2 1,500–3,576 1,582–4,198.5
CNVM lesion type
Occult, no. (%) 484 (49.0) 317 (65.5) 113 (23.3) 54 (11.2) 0.001*
IPCV, no. (%) 132 (13.4) 76 (57.6) 29 (22.0) 27 (20.5)
Minimally classic, no. (%) 71 (13.4) 38 (53.5) 22 (31.0) 11 (15.5)
Predominantly classic, no. (%) 157 (15.9) 75 (47.8) 63 (40.1) 19 (12.1)
Other, no. (%) 66 (6.7) 40 (60.6) 17 (25.8) 9 (13.6)
Not done, no. (%) 77 (7.8) 48 (62.3) 21 (27.3) 8 (10.4)
Country
Australia (%) 471 (47.7) 276 (58.6) 159 (33.7) 36 (7.6)
Switzerland (%) 203 (20.6) 128 (63.1) 26 (12.8) 49 (24.1)
Singapore (%) 195 (19.8) 121 (62.1) 40 (20.5) 34 (17.4)
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was also analyzed to reflect the treatment regimen. We
found 66.2% of patients had a treatment regimen con-
sistent with treat and extend (received an injection in
.80% of visits), while 33.8% had a regimen consis-
tent with pro re nata (received an injection in#80% of
visits).
Treatment Effect Based on Smoking Status
Visual acuity for all groups combined improved by
a raw mean of 5.9 letters of change (4.9–6.9 95% CI)
over 12 months. There was a significant difference in
adjusted mean improvement in visual acuity at 12
months between nonsmokers, ex-smokers, and smok-
ers for completers and noncompleters combined (8.0
vs. 5.9 vs. 4.6 letters of change, respectively; P =
0.040) (Table 2). A significant difference in adjusted
mean improvement was also seen when only com-
pleters where analyzed (7.7 vs. 6.1 vs. 3.5 letters of
change, respectively; P = 0.046). Pairwise comparison
between groups did not clearly define which pairs dif-
fered significantly.
The modeled visual acuity curves over 12 months of
the different groups were significantly different (P ,
0.001) (Figure 1), indicating different treatment trajec-
tories between the groups. The median number of
treatments over 12 months was the same for all 3
groups (Table 2). Visual outcome after 24 months
was available in 538 of the 758 patients included in
the 12-month analysis. The smoker group (n = 68) still
had numerically lower visual gain, although the differ-
ence was not statistically significant. Nonsmokers, ex-
smokers, and smokers gained 6.7 v 5.2 v 3.7 letters of
change, respectively, over 24 months (P = 0.134).
Despite this, the modeled curves of visual acuity meas-
urements over 24 months were significantly different
among the three groups (P , 0.001) (Figure 1).
Kaplan–Meier survival analysis of the proportion of
patients with active CNVM showed a trend of non-
smokers being graded as inactive sooner than ex-
smokers or smokers (Figure 2). Median time after
starting treatment to when the CNVM was first graded
as inactive did not differ significantly between non-
smokers, ex-smokers, and smokers (99 v 91 v 111
days; P = 0.153) (Table 2).
Discussion
This analysis on the effect of smoking on outcomes
of treatment of nAMD found significant differences
between smoking groups for age, baseline visual
acuity, and baseline CNVM size when they started
treatment. The younger age of smokers is likely to be
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increased risk of developing nAMD than non-
smokers.7,11 Despite being younger, these patients also
seemed to have more aggressive disease, with worse
baseline visual acuity and larger CNVM. This result is
consistent with a Welsh study that also investigated
smoking and VEGF inhibitors.25 Men were relatively
overrepresented in both the ex-smoker and smoker
cohorts in our study, which is consistent with world-
wide prevalence rates of smoking for men (31.1%–
48.6%) and women (6.2%–11.3%).26–28 Female smok-
ers have also been estimated to smoke 20% less ciga-
rettes a day than male smokers.29 This is particularly
meaningful in the setting of the established dose–
response effect of pack-years and subsequent progres-
sion of nAMD.13,30–32 Of concern, a recent British
study reported that only 53.1% of smokers with
AMD recalled that they were advised to quit smoking
by their ophthalmologist or optometrist.33
The adjusted mean visual acuity improvement at 12
months was significantly different among the three
groups. Nonsmokers had more than twice the gain in
visual acuity after 12 months than smokers. Despite
this, we were not able to determine with confidence
which pairs differ significantly. The same pattern was
observed in the 3 groups at 24 months, although the
difference between adjusted mean visual acuity change
was not statistically significant. Despite the known
“ceiling effect” of eyes with better baseline visual acu-
ity having less room to improve, nonsmokers had bet-
ter visual acuity gains even when they had better
baseline visual acuity. The differences in the modeled
curves of the mean visual acuity change over 12 month
and 24 months were also statistically significant. Quit-
ting smoking may lead to better visual outcomes after
1 year of treatment, since ex-smokers gained a mean of
6.1 letters versus 3.5 letters for smokers, but further
studies would be required to determine whether this
association is statistically significant.
The outcomes we found in smokers receiving VEGF
inhibitors add to a pool of varied results from other
studies. The Comparison of Age-related Macular
Degeneration Treatments Trials (CATT) presented
cohort outcomes for ranibizumab or bevacizumab at
12 months for 1,105 patients dependent on smoking
status.22 They found no statistically significant effect
of smoking, although they did not adjust for baseline
age, baseline visual acuity, and type or size of CNVM,
all of which were associated with significant differ-
ences in outcomes in their data, as well as our
own.22 The 5-year follow-up analysis of the CATT
cohort, however, reported smoking was significantly
and independently associated with worse long-term
vision outcomes.34 Two Korean studies investigated
the prevalence of smokers in those who were poor
responders to VEGF inhibitors but found contrasting
results.21,35 A relatively small Japanese case–control
study of 64 eyes found no effect of smoking on out-
comes of treatment with ranibizumab or aflibercept,
although they reported significant central retinal thin-
ning in smokers.36 A prospective U.K. study of 106
eyes found similar absolute values for each group but
was not statistically significant.37 An Italian study of
ranibizumab usage found better visual outcomes in
never smokers by five letters.38 The strengths of our
methods were the use of a real world database, as well
as adjusting for significant confounders such as base-
line visual acuity.
The mechanism of any potential association
between current smokers and poorer visual outcomes
with VEGF inhibitors is unclear. A genetic back-
ground may aggravate the detrimental effect that
smoking has on treatment outcomes for nAMD.39
Whole genome sequencing has associated many single
Fig. 1. Generalized additive model of visual acuity over first 24 months
of VEGF inhibitor treatment by smoking status.
Fig. 2. Kaplan–Meier estimator of proportion of patients with lesions
still active over time dependent on smoking status.
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nucleotide polymorphisms with AMD, including com-
plement factor H,37,40,41 age-related maculopathy
susceptibility-2 (ARMS2),42 and high-temperature
requirement A-1.37,42 Combining previous smoking
history with these “at-risk” alleles has been reported
to account for up to a 8-letter difference in visual out-
comes.38 Smokers homozygous for the at-risk comple-
ment factor H allele have a reported odds ratio of 8.7
to 34.5 for late AMD,43,44 while smokers homozygous
for ARMS2 have an estimated OR of 8.2 to 23.3.43–45
Similarly, it has been suggested that smoking history
in combination with complement factor H and
ARMS2 mutations confers a greater risk than each
factor alone.44 The increased time to CNVM inactivity
found in current smokers did not reach statistical sig-
nificance. Cigarette smoking causing an increase in
autophagic flux and thereby further degradation of
the retinal pigment epithelium has been suggested as
a causative mechanism in recent studies.46 Smoking
history has also been associated with decreased mean
central macular choroidal thickness.47 A prospective
study analyzing the effect of smoking status on central
macular choroidal thickness, persistence of subretinal
fluid, and visual acuity in VEGF inhibitor–treated
nAMD may clarify the causal mechanism of
decreased treatment efficacy.
There are some limitations to our study. The 12-
month dropout rate of 23% was typical of observa-
tional studies but still high. The mean visual acuity
change at the last observed visit for dropouts was still
quite good, suggesting many eyes may have been lost
to follow-up due to reasons unrelated to treatment
outcomes such as going to another doctor, as we have
previously reported in an analysis of participants in
this database.48 We did not distinguish between bev-
acizumab, ranibizumab, and aflibercept since the anal-
ysis included data before the introduction of
aflibercept in 2012 to 2013, although real-world stud-
ies have reported similar outcomes between these
drugs.49–51 Measurement of smoking status as current,
ex-smoker, or nonsmoker rather than utilization of
pack-years did not allow for establishment of any
dose–response relationship. Nor was it known when
ex-smokers quit; some patients may have quit more
recently than others or taken up smoking again during
the follow-up period. Regardless, ex-smokers were
observed to achieve intermediate outcomes between
nonsmokers and smokers.
To conclude, we have collated data over 11 years of
treatment of nAMD from multiple practices and
countries. The adjusted visual acuity change at both
12 months and 24 months consistently found less
improvement for current smokers than for never
smokers, with past smokers in between. Curves
modeling visual acuity also showed a highly signifi-
cant difference in visual acuity outcomes over the 24
months of treatment dependent on smoking status.
Although some small reports have found no such
association, our study complements others that have
linked smoking with inferior nAMD treatment out-
comes. This may be used as an extra inducement for
smokers to quit when they start treatment.
Key words: aflibercept, AMD, bevacizumab, ciga-
rette, ranibizumab, nicotine.
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